Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Receivables

Latest receivables for AIDX: $290K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$291486.00

Peer trimmed avg / median

Loading

20/20 Biolabs Common Stock Receivables History

Loading

20/20 Biolabs Common Stock vs. peers: Receivables Comparison

Loading

20/20 Biolabs Common Stock Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

20/20 Biolabs Common Stock (AIDX) currently reports a receivables of $290K as of June 2026. Use the charts on this page to explore 20/20 Biolabs Common Stock's receivables history and peer comparisons.

20/20 Biolabs Common Stock reported $290K in receivables as of June 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $290K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for 20/20 Biolabs Common Stock, and consider following AIDX for alerts when major investors trade the stock.